Achieve Life Sciences Q2 net loss rises to $74.8 million on warrant charge
Achieve Life Sciences reported a second-quarter 2026 net loss of $74.8 million, up from $12.7 million a year earlier, with no revenue reported. The loss includes a non-cash $48.7 million charge tied to the change in fair value of warrant liabilities from its private placement, and the company said it plans to resubmit its cytisinicline NDA in the fourth quarter of 2026 after a June 20, 2026 Complete Response Letter from the FDA.
Key points
- Q2 2026 net loss was $74.8 million, or $0.80 per share, versus a net loss of $12.7 million, or $0.37 per share, in Q2 2025.
- The quarter includes a non-cash $48.7 million charge related to changes in the fair value of warrant liabilities from the private placement.
- Total operating expenses were $18.4 million versus $12.6 million a year earlier; cash, cash equivalents and marketable securities were $187.3 million as of June 30, 2026.
- On June 20, 2026, the FDA issued a Complete Response Letter; the company plans NDA resubmission in Q4 2026 and anticipates potential approval in the first half of 2027.
The filing
Written by AI on Nov 9, 2026, 8:29 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 11, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.